Double-blind comparison of 30 and 60 mg tranylcypromine daily in patients with panic disorder comorbid with social anxiety disorder

Psychiatry Research

Volumn 175, Issue 3, 2010, Pages 260-265

  Nardi, Antonio E ^a   Lopes, Fabiana L ^a   Valença, Alexandre M ^a   Freire, Rafael C ^a   Nascimento, Isabella ^a   Veras, Andre B ^a   Mezzasalma, Marco A ^a   de Melo Neto, Valfrido L ^a   Soares Filho, Gastão L ^a   King, Anna Lucia ^a   Grivet, Leila O ^a   Rassi, Arabella ^a   Versiani, Marcio ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Antidepressant; Anxiety disorder; Monoamine oxidase inhibitor; Phobic disorder; Prognosis; Tranylcypromine

Indexed keywords

PLACEBO; TRANYLCYPROMINE;

ADULT; ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; EJACULATION DISORDER; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INSOMNIA; LIBIDO DISORDER; MALE; NAUSEA; OUTCOME ASSESSMENT; PANIC; PRIORITY JOURNAL; QUESTIONNAIRE; SCORING SYSTEM; SOCIAL PHOBIA; SOMNOLENCE; SYMPTOM; TREATMENT DURATION; XEROSTOMIA;

ADULT; ANALYSIS OF VARIANCE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; PANIC DISORDER; PHOBIC DISORDERS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TRANYLCYPROMINE;

EID: 73449083350     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2008.06.025     Document Type: Article

References (34)

1. Arnot R. Calming effects of the monoamine oxidase inhibitors. Diseases of the Nervous System 11 (1960) 448
2. Balon R., Mufti R., and Arfken C.L. A survey of prescribing practices for monoamine oxidase inhibitors. Psychiatric Services 50 (1999) 945-947
3. Bechelli L.P., Nardi A.E., and Alves A.B. Review of the use of the irreversible monoamine oxidase inhibitors (MAOIs) in psychiatry. Current Medical Research Opinions 11 S1 (1989) 38-52
4. Deltito J.A., and Perugi G. A case of social phobia with avoidant personality disorder treated with MAOI. Comprehensive Psychiatry 27 (1986) 255-258
5. Endicott J., Nee J., Harrison W., and Blumenthal R. Quality of Life Enjoyment and Satisfation Questionnaire: a new measure. Psychopharmacology Bulletin 29 (1993) 321-326
6. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.M. Structured Clinical Interview Diagnostic (SCID) for DSM-IV Axis I Disorders - Clinician Version (SCID-CV) (1997), American Psychiatric Press, Washington, DC
7. Frances A., Widiger T., and Fyer M.R. The influence of classification methods on comorbidity. In: Maser J.D., and Cloninger C.R. (Eds). Comorbidity of Mood and Anxiety Disorders (1990), American Psychiatric Press, Washington, DC 41-60
8. Goldstein S. Three cases of overlap between panic disorder, social phobia, and agoraphobia. Journal of Clinical Psychiatry 48 (1987) 452-453
9. Goodwin R.D., and Hamilton S.P. Lifetime comorbidity of antisocial personality disorder and anxiety disorders among adults in the community. Psychiatry Research 117 (2003) 159-166
10. Gorman J.M., Kent J.M., Sullivan G.M., and Coplan J.D. Neuroanatomical hypothesis of panic disorder, revised. American Journal of Psychiatry 157 (2000) 493-505
11. Guy, W. (Ed.), 1976. ECDEU Assessment Manual for Psychopharmacology, Revised. DHEW Publication. Superintendent of Documents, Government Printing Office, Washington, DC.
12. Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 32 (1959) 50-55
13. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry 23 (1960) 56-62
14. Jann M.W., and Kurtz N.M. Treatment of panic and phobic disorders. Clinical Pharmacology 6 (1987) 947-962
15. Liebowitz M.R., Fyer A.J., Gorman J.M., Campeas R., and Levin A. Phenelzine in social phobia. Journal of Clinical Psychopharmacology 6 (1986) 93-98
16. Liebowitz M.R., Gorman J.M., Fyer A.J., Campeas R., Levin A.P., Sandberg D., Hollander E., Papp L., and Goetz D. Pharmacotherapy of social phobia: an interim report of a placebo-controlled comparison of phenelzine and atenolol. Journal of Clinical Psychiatry 49 (1988) 242-257
17. Liebowitz M.R., Gorman J.M., Fyer A.J., and Klein D.F. Social phobia. Review of a neglected anxiety disorder. Archives of General Psychiatry 42 (1985) 729-736
18. Nutt D.J., and Lawson C. Panic attacks: a neurochemical overview of models and mechanisms. British Journal of Psychiatry 160 (1992) 390-396
19. Perugi G., Nassini S., Socci C., Lenzi M., Toni C., Simonini E., and Akiskal H.S. Avoidant personality in social phobia and panic-agoraphobic disorder: a comparison. Journal of Affective Disorders 54 (1999) 277-282
20. Quitkin F.M., McGrath P.J., Stewart J.W., Harrison W., Tricamo E., Wager S.G., Ocepek-Welikson K., Nunes E., Rabkin J.G., and Klein D.F. Atypical depression, panic attacks, and response to imipramine and phenelzine: a replication. Archives of General Psychiatry 47 (1990) 935-941
21. Rapaport M.H., Pollack M., Wolkow R., Mardekian J., and Clary C. Is placebo response the same as drug response in panic disorder. American Journal of Psychiatry 157 (2000) 1014-1016
22. Ressler K.J., and Nemeroff C.B. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depression and Anxiety 12 suppl. 1 (2000) 2-19
23. Roy-Byrne P.P., Craske M.G., and Stein M.B. Panic disorder. Lancet 368 (2006) 023-1032
24. Sargant W. Treatment of the phobic anxiety state. British Medical Journal 3 (1969) 49
25. Shear M.K., Brown T.A., Barlow D.H., Money R., Sholomskas D., Woods S.W., Gorman J.M., and Papp L.A. Multicenter Collaborative Panic Disorder Severity Scale. American Journal of Psychiatry 154 (1997) 1571-1575
26. Sheehan D.V. The Anxiety Disease (1983), Charles Scribners & Sons, New York
27. Sheehan D.V., Ballenger J., and Jacobson G. Treatment of endogenous anxiety with phobic, hysterical and hypochondrial symptoms. Archives of General Psychiatry 37 (1980) 51-59
28. Simpson H.B., Schneier F.R., Campeas R.B., Marshall R.D., Fallon B.A., Davies S., Klein D.F., and Liebowitz M.R. Imipramine in the treatment of social phobia. Journal of Clinical Psychopharmacology 18 (1998) 132-135
29. Stein M.B., Tancer M.E., Gelernter C.S., Vittone B.J., and Uhde T.W. Major depression in patients with social phobia. American Journal of Psychiatry 147 (1990) 637-639
30. Tyrer P., and Shawcross C. Monoamine oxidase inhibitors in anxiety disorders. Journal of Psychiatric Research 1 22 Suppl (1988) 87-98
31. Tyrer P.J., Candy J., and Kelly D. A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety. Psychopharmacologia 32 (1973) 237-254
32. Versiani M., Costa e Silva J.A., and Klerman G.L. Treatment of Panic Disorder with Alprazolam, Imipramine, Tranylcypromine or Placebo. Annual Meeting of the American College of Neuropsychopharmacology (1987) 276 San Juan, Puerto Rico
33. Versiani M., Mundim F.D., Nardi A.E., and Liebowitz M.R. Tranylcypromine in social phobia. Journal of Clinical Psychopharmacology 8 (1988) 279-283
34. Versiani M., Nardi A.E., Mundim F.D., Liebowitz M.R., and Amrein R. social phobia: a controlled study with moclobemide and phenelzine. British Journal of Psychiatry 161 (1992) 353-360